menu
    • menu
    [{"orgOrder":0,"company":"North China Pharmaceutical Co., Ltd.","sponsor":"North China Pharmaceutical Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"North China Pharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Pill","sponsorNew":"North China Pharmaceutical Co., Ltd. \/ North China Pharmaceutical Co., Ltd.","highestDevelopmentStatusID":"11","companyTruncated":"North China Pharmaceutical Co., Ltd. \/ North China Pharmaceutical Co., Ltd."},{"orgOrder":0,"company":"North China Pharmaceutical Co., Ltd.","sponsor":"North China Pharmaceutical Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"North China Pharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"North China Pharmaceutical Co., Ltd. \/ North China Pharmaceutical Co., Ltd.","highestDevelopmentStatusID":"9","companyTruncated":"North China Pharmaceutical Co., Ltd. \/ North China Pharmaceutical Co., Ltd."},{"orgOrder":0,"company":"North China Pharmaceutical Co., Ltd.","sponsor":"North China Pharmaceutical Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"North China Pharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"North China Pharmaceutical Co., Ltd. \/ North China Pharmaceutical Co., Ltd.","highestDevelopmentStatusID":"8","companyTruncated":"North China Pharmaceutical Co., Ltd. \/ North China Pharmaceutical Co., Ltd."},{"orgOrder":0,"company":"North China Pharmaceutical Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2011","type":"Inapplicable","leadProduct":"Shenwu","moa":"Immune","graph1":"Neurology","graph2":"Phase III","graph3":"North China Pharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"North China Pharmaceutical Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"North China Pharmaceutical Co., Ltd. \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by North China Pharmaceutical Co., Ltd.

    Menu

    North China Pharmaceutical Co., Ltd.

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            North China Pharmaceutical Co., Ltd.

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            North China Pharmaceutical Co., Ltd.

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sirolimus

                            Therapeutic Area : Immunology

                            Study Phase : Phase IV

                            Recipient : Peking University First Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sirolimus Monotherapy in the Treatment of Antiphospholipid Antibody Related Thrombocytopenia

                            Details : Sirolimus is a Antibiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Antiphospholipid Syndrome.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            December 09, 2024

                            Lead Product(s) : Sirolimus

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase IV

                            Recipient : Peking University First Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            North China Pharmaceutical Co., Ltd.

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            North China Pharmaceutical Co., Ltd.

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sirolimus

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II/ Phase III

                            Recipient : Peking Union Medical College Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sirolimus in Treatment of Proteinuric Flares of Lupus Nephritis

                            Details : Sirolimus is a Antibiotic drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Lupus Nephritis.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            May 19, 2021

                            Lead Product(s) : Sirolimus

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II/ Phase III

                            Recipient : Peking Union Medical College Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            North China Pharmaceutical Co., Ltd.

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            North China Pharmaceutical Co., Ltd.

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sirolimus

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Recipient : Peking Union Medical College Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Efficacy and Safety of Sirolimus for Plastic Bronchitis

                            Details : Sirolimus is a Antibiotic drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Bronchitis.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            May 08, 2019

                            Lead Product(s) : Sirolimus

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Recipient : Peking Union Medical College Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            North China Pharmaceutical Co., Ltd.

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            North China Pharmaceutical Co., Ltd.

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Shenwu

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety Study of Shenwu Capsule

                            Details : Shenwu is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Cognitive Dysfunction.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            October 14, 2011

                            Lead Product(s) : Shenwu

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth